Transaera, Inc. | $10,500,000 | (Nov 5, 2024)
Algebrik AI | $4,000,000 | (Nov 5, 2024)
cloudsquid | $1,000,000 | (Nov 5, 2024)
Smartlens
United States
- Mountain View, California
- 12/07/2023
- Series A
- $6,100,000
Smartlens is a clinical-stage company with its portfolio of innovative technologies for diagnosing and treating glaucoma, a chronic eye disease that ranks as the leading cause of irreversible blindness.
The Company's flagship product, miLens, is an innovative, non-invasive, contact lens-based device capable of monitoring intraocular pressure—the primary and only treatable risk factor for glaucoma. This addresses a significant unmet need that has persisted since the 1950s.
Strong clinical results for miLens were presented at the American Glaucoma Society 2023 meeting. The Company plans to commercialize miLens in 2024.
miLens utilizes a unique, electronics-free sensor technology owned by Smartlens and protected by a portfolio of patents spanning more than 40 countries. Additionally, Smartlens owns THERmic, an advanced non-invasive drug delivery technology that helps prevent disease progression, enhances treatment effectiveness by offering personalized therapies for individual patients. It also lays the foundation for a new generation of therapies.
Smartlens has received investments from prominent institutions, venture capital firms, Stanford University, and key opinion leaders.
In recognition of its accomplishments, Smartlens was honored with the "Outstanding Innovation in Medical Technology and Life Sciences" award at the 2021 High-Tech Awards by Octane. The company’s technologies have also been recognized by reputable sources such as Nature Medicine, Fortune, BBC, and ABC News.
Smartlens envisions a world where Glaucoma can no longer rob people of their vision and quality of life.
- Industry Medical Equipment Manufacturing
- Website https://www.smartlens.health/
- LinkedIn https://www.linkedin.com/company/smartlens-health/
Related People
Savas KombanCo Founder
United States -
Palo Alto, California
Savas Komban is a serial entrepreneur with more than 25 years of experience. Savas has been featured on Fortune's "40 Under 40" list, has developed high-performing teams, and has achieved successful M&As with Fortune 50 companies where he held senior leadership roles on a global scale. He has founded businesses that have been recognized as outstanding innovations improving the world and listed among Deloitte's fastest-growing companies for seven consecutive years.
As the CEO and Co-Founder of Smartlens, Savas is passionate about building innovative solutions for diagnosing and treating glaucoma, a chronic eye disease that ranks as the leading cause of irreversible blindness. The company has a portfolio of clinical-stage, non-invasive technologies that help prevent disease progression and enhance treatment effectiveness by offering personalized therapies for individual patients. These technologies are also paving the way for the development of a new generation of therapies.
Under his leadership, Smartlens has achieved strong clinical results and received investments from prominent institutions, venture capital firms, Stanford University, and key opinion leaders.
Earlier in his career, Savas founded itelligence TR, rapidly growing the business from the ground up to a global scale, leading to its acquisition by the Japanese company, NTT. He continued as its President & CEO and Head of Global Business Innovation for NTTD, where he led the transformation from a mid-sized corporation to a large-scale global enterprise, growing the business fivefold in four years. The organization has developed breakthrough technologies and has been selected as a top digital innovator by institutions such as SAP and Deloitte.
In addition to his track record as a business leader, Savas has extensive experience in business innovation, stemming from his work steering the digital transformation of enterprises and increasing their overall efficiency.
Cintoo | $40,246,701 | (Nov 5, 2024)
Further | $4,100,000 | (Nov 5, 2024)
Plato | $6,500,000 | (Nov 5, 2024)
Advex AI | $3,500,000 | (Nov 5, 2024)
Birl | $647,878 | (Nov 5, 2024)
Insider. | $500,000,000 | (Nov 5, 2024)
OpenOrigins | $4,500,000 | (Nov 1, 2024)
Persana AI | $2,300,000 | (Nov 1, 2024)
Definition Health | $7,412,756 | (Nov 1, 2024)